



**23 August 2018**

ASX Announcement

## Management and services changes at Race Oncology

---

**Thursday, 23 August 2018: Race Oncology Limited ('RAC')** has announced that Dr John Rothman will step down as full-time Chief Scientific Officer for Race Oncology, from 31 August 2018.

Dr Rothman will continue as a part-time consultant for the Company from 1 September to 31 December 2018. Race is arranging consulting services to cover Dr Rothman's responsibilities during the transition phase and beyond the end of the year.

"As the founding Chief Scientist for Race Oncology, John Rothman has been vital to our first two years of operation and we are truly grateful for all his work in managing the patents, FDA relations and manufacturing activities," stated Peter Molloy, Race CEO.

Following the appointment of Dr Samar Al-Behaisi to head the Named Patient Program (NPP) in Europe, the Company also advised that the consulting agreement for Gordon Beck (Vice President Business Development) has been terminated and that notice of termination has been provided to CarthaGenetics relating to their NPP representation services in Europe.

"These changes reflect a strategic refocusing of the Company's NPP activities around Samar Al-Behaisi, as well as prudent cost management," said Mr Molloy.

### **About Race Oncology (RAC.ASX)**

Race Oncology is a specialty pharmaceutical company that listed on the Australian Securities Exchange (ASX) in July 2016. Race's business model is to pursue later-stage drug assets in the cancer field that have been overlooked by big pharma. The company's first asset is Bisantrane. Race has successfully manufactured Bisantrane and is seeking to complete the development necessary to gain FDA approval, while also making the drug available as an unlicensed medication under named patient programs outside the US.

### Media contact:

Heidi Cuthbert, +61 411 272 366;  
E: [heidi.cuthbert@multiplier.com.au](mailto:heidi.cuthbert@multiplier.com.au)